Among them, DESTINY-Breast05 (NCT04622319) focuses on high-risk HER2-positive primary breast cancer patients who still have invasive lesions in the breast or axillary lymph nodes after receiving neoadjuvant therapy. The gene discussed is ERBB2; the disease is breast carcinoma.